Some new info hidden away in SBNs half yearly report released last night which is interesting and has not been announced to market before. Previously their single product was Oraline on it's own as a substance abuse test. Now in addition to this they are exploring other applications with their IP. Low market cap and an OK cash balance, I have held this for a few months now and still believe there is heaps of upside given the new board and refocus.
